Immuron Ltd — Capital/Financing Update 2018

Mar 15, 2018

==> picture [197 x 56] intentionally omitted <==

Immuron Completes A$5.1M Placement to US Fund

Melbourne, Australia, March 16, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is pleased to advise of the completion of its $5.1M private placement to a large U.S. institutional investment fund.

As previously announced, the terms of the private placement raised Immuron approximately A$5.1 million (before costs of the offer) for the issuance of 13,162,744 new ASX shares at A$0.39 per share, plus three new free-attaching options for every 5 new shares issued resulting in 7,897,647 new options being issued exercisable at A$0.468 per option, expiring 5 years from the date of issue.

The following information is provided as required under LR3.10.5A:

The Company issued 12,931,546 fully paid ordinary shares under its 10% capacity under Listing Rule 7.1A (Capacity Shares), representing part of the total number of securities issued under this private placement.

Further information as required:

• a) the dilutive effect on existing shareholders of the 10% Capacity Shares is as follows:

No. of shares on issueprior toprivateplacement	129,615,462
Shares issued to investor under LR7.1A(CapacityShares)	12,961,546
Dilution as a result of issue under LR7.1A	10%
Shares issued to investor under LR7.1 aspart of thisplacement	201,198
Total number of shares now on issue	142,778,206

• b) the placement was undertaken following identified demand for shares the Company’s securities by a large US institutional investment fund. The issue price per share under the placement was $0.39, representing a 2.70% discount to the volume weighted average price (VWAP) for the 15 days on which trades of the Company’s shares were recorded on ASX ending on 13 March 2018 (data obtained from Commsec).

The private placement to one large US fund was considered the most efficient and effective method of meeting this identified demand to secure future funding for the Company’s ongoing clinical programs, support marketing initiatives surrounding the Company’s flagship product Travelan, which has already experienced significant sales growth through the first half of financial year 2018, and provide ongoing working capital for the Company.

• c) There was no underwriting agreement in relation to this placement. As joint placement agents for the offering, Joseph Gunnar & Co., LLC and H.C. Wainwright & Co. each received a 4% fee for funds raised, plus 4% option coverage for every share issued.

==> picture [591 x 63] intentionally omitted <==

==> picture [134 x 39] intentionally omitted <==

d) Standard commercial legal, placement and issuances fees were payable on the offer and placement.

Further details regarding the issue of the shares are contained within the accompanying Appendix 3B.

• • • END - - -

COMPANY CONTACT: USA INVESTOR RELATIONS: AUS INVESTOR RELATIONS: Jerry Kanellos Jon Cunningham Peter Taylor Chief Executive Officer (Interim) RedChip Companies, Inc. NWR Communications Ph: +61 (0)3 9824 5254 US Ph: +1 (407) 644 4256, (ext. 107) Ph: +61 (0)412 036 231 jerrykanellos@immuron.com jon@redchip.com peter@nwrcommunications.com.au

ABOUT IMMURON:

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of Travelers’ Diarrhea and its lead clinical candidate, IMM-124E, is in Phase II clinical trials for Non-Alcoholic Steatohepatitis (NASH), Severe Alcoholic Hepatitis (SAH) and Pediatric Nonalcoholic Fatty Liver Disease (NAFLD). Immuron’s second clinical stage asset, IMM-529, is targeting Clostridium difficile Infections (CDI). These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the global immunotherapy market.

For more information visit: http://www.immuron.com

==> picture [489 x 32] intentionally omitted <==

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

==> picture [595 x 64] intentionally omitted <==

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New Issue Announcement, Application for Quotation of Additional Securities and Agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of Entity

Immuron Limited (ASX: IMC) (NASDAQ: IMRN)

ABN

80 063 114 045

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued a) Ordinary Shares (IMC) b) Options over ordinary shares (New Class) c) Options over ordinary shares (New Class) d) NASDAQ American Depository Receipts (ADRs) 2 Number of[+] securities issued or to be issued a) 13,162,744 (if known) or maximum number which may b) 7,897,647 be issued c) 526,510 d) 7,500 3 Principal terms of the[+] securities (e.g. if a) Ordinary Fully Paid Shares (IMC) options, exercise price and expiry date; if b) Unlisted options exercisable at $0.468 on or before partly paid +securities, the amount 15 March 2023 outstanding and due dates for payment; if + c) Unlisted options exercisable at $0.585 on or before convertible securities, the conversion price 15 March 2023 and dates for conversion) d) NASDAQ Fully Paid ADRs (IMRN)

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B Page 1

4 Do the+securities rank equally in all respects from the+issue date with an existing+class of quoted+securities? If the additional+securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an+eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6hin relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of +securities issued without security holder approval under rule 7.1 6d Number of+securities issued with security holder approval under rule 7.1A 6e Number of+securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	a) Yes (IMC) b) Yes, upon exercise (IMC) c) Yes, upon exercise (IMC) d) Yes, (IMRN)
	a) $5,133,470 b) NIL – New free-attaching 3 options for every 5 new shares. c) NIL – Broker shares as part of placement fee. d) USD$75,000
	a), b), & c) Private Placement to Institution Investment Fund. Funds raised from the placement will fund Immuron’s ongoing clinical programs, support marketing initiatives surrounding the Company’s flagship product Travelan, and provide ongoing working capital for the Company. d) Exercise of NASDAQ Warrants (IMRNW)
	Yes
	13 November 2017
	8,625,355
	12,961,546
	Nil

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B Page 2

6f Number of+securities issued under an exception in rule 7.2 6g If+securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. 6h If+securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 +Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	Nil
	Yes, refer to the accompanying announcement.
	N/A
	Refer to the attached Appendix 1
	Friday 16thMarch 2018

Number 8 Number and+class of all+securities quoted on ASX (includingthe +securities in section 2 if applicable) 142,778,206 25,289,894 9 Number and+class of all +securities not quoted on ASX (includingthe+securities in section 2 if applicable) Qty Amount 1,050,000 1,000,000 15,380 140,056 7,625,532 14,493 29,668 27,760,000 (694,000 Warrants) 7,897,647 526,510 46,059,286	Number 8 Number and+class of all+securities quoted on ASX (includingthe +securities in section 2 if applicable) 142,778,206 25,289,894 9 Number and+class of all +securities not quoted on ASX (includingthe+securities in section 2 if applicable) Qty Amount 1,050,000 1,000,000 15,380 140,056 7,625,532 14,493 29,668 27,760,000 (694,000 Warrants) 7,897,647 526,510 46,059,286	Number 8 Number and+class of all+securities quoted on ASX (includingthe +securities in section 2 if applicable) 142,778,206 25,289,894 9 Number and+class of all +securities not quoted on ASX (includingthe+securities in section 2 if applicable) Qty Amount 1,050,000 1,000,000 15,380 140,056 7,625,532 14,493 29,668 27,760,000 (694,000 Warrants) 7,897,647 526,510 46,059,286	Number	+Class	+Class	+Class
			142,778,206 25,289,894	Fully Paid Ordinary Shares (IMC) Listed Options (IMCOB) exercisable at A$0.55 on or before 30 Nov 2019
				+Class(Options over OrdinaryShares) Exercise Price Expiration Date ASX Code AUD$0.500 1 Oct 2018 IMCAC AUD$0.570 24 Feb 2019 IMCAI AUD$1.892 28 Feb 2019 IMCAI AUD$0.300 28 May 2019 IMCAI AUD$0.500 27 Nov 2019 IMCAI AUD$1.944 30 Nov 2021 IMCRM1 AUD$1.876 17 Jan 2022 IMCRM2 USD$10.00 for every40 options 13 Jun 2022 IMCAI AUD$0.4680 15 Mar 2023 New Class AUD$0.5850 15 Mar 2023 New Class TOTAL
			Qty	+Class(Options over OrdinaryShares)
			Amount	Exercise Price	Expiration Date	ASX Code
			1,050,000	AUD$0.500	1 Oct 2018	IMCAC
			1,000,000	AUD$0.570	24 Feb 2019	IMCAI
			15,380	AUD$1.892	28 Feb 2019	IMCAI
			140,056	AUD$0.300	28 May 2019	IMCAI
			7,625,532	AUD$0.500	27 Nov 2019	IMCAI
			14,493	AUD$1.944	30 Nov 2021	IMCRM1
			29,668	AUD$1.876	17 Jan 2022	IMCRM2
		27,760,000 (694,000 Warrants)		USD$10.00 for every40 options	13 Jun 2022	IMCAI
		7,897,647		AUD$0.4680	15 Mar 2023	New Class
		526,510		AUD$0.5850	15 Mar 2023	New Class
		46,059,286		TOTAL

10 Dividend policy (in the case of a Unchanged trust, distribution policy) on the increased capital (interests)

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B Page 3

Part 2 - Pro rata issue

11 Is security holder approval required? 12 Is the issue renounceable or non- renounceable? 13 Ratio in which the+securities will be offered 14 +Class of+securities to which the offer relates 15 +Record date to determine entitlements 16 Will holdings on different registers (or sub-registers) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions 18 Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 19 Closing date for receipt of acceptances or renunciations 20 Names of any underwriters 21 Amount of any underwriting fee or commission 22 Names of any brokers to the issue 23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	-
	-
	-
	-
	-
	-
	-
	-
	-
	-
	-
	-
	-
	-

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B Page 4

25 If the issue is contingent on security holders’ approval, the date of the meeting 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do security holders sell their entitlementsin fullthrough a broker? 31 How do security holders sellpartof their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)? 33 +Issue date	-
	-
	-
	-
	-
	-
	-
	-
	-

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of[+] securities (tick one)

• (a) +Securities described in Part 1

• (b) All other[+] securities

• Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B Page 5

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the+securities are+equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional+securities held by those holders 36 If the+securities are+equity securities, a distribution schedule of the additional+securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional+securities Entities that have ticked box 34(b) 38 Number of+securities for which+quotation is sought 39 +Class of+securities for which quotation is sought 40 Do the+securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional+securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another+security, clearly identify that other+security) Number +Class 42 Number and+class of all+securities quoted on ASX (includingthe+securities in clause 38)	35 If the+securities are+equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional+securities held by those holders 36 If the+securities are+equity securities, a distribution schedule of the additional+securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional+securities Entities that have ticked box 34(b) 38 Number of+securities for which+quotation is sought 39 +Class of+securities for which quotation is sought 40 Do the+securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional+securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another+security, clearly identify that other+security) Number +Class 42 Number and+class of all+securities quoted on ASX (includingthe+securities in clause 38)	35 If the+securities are+equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional+securities held by those holders 36 If the+securities are+equity securities, a distribution schedule of the additional+securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional+securities Entities that have ticked box 34(b) 38 Number of+securities for which+quotation is sought 39 +Class of+securities for which quotation is sought 40 Do the+securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional+securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another+security, clearly identify that other+security) Number +Class 42 Number and+class of all+securities quoted on ASX (includingthe+securities in clause 38)
	Number	+Class

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B Page 6

Quotation agreement

• 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

• 2 We warrant the following to ASX.

• The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

• There is no reason why those[+] securities should not be granted[+] quotation.

• An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

• If we are a trust, we warrant that no person has the right to return the[+] securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

• 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

• 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before[+] quotation of the[+] securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ______ Date: Friday, 16[th] March 2018 Company Secretary & CFO Print name: Peter Vaughan

==> picture [38 x 22] intentionally omitted <==

The CFO Solution

Friday 16 March 2018

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B Page 7

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

Insert number of fully paid[+] ordinary securities on issue 105,641,417 12 months before the[+] issue date or date of agreement to issue Add the following:

• Number of fully paid[+] ordinary securities issued in 25,575,000 (LR 7.3) that 12 month period under an exception in rule 7.2 399,045 (LR 7.4)

• Number of fully paid[+] ordinary securities issued in that 12 month period with shareholder approval

• Number of partly paid[+] ordinary securities that became fully paid in that 12 month period

Note:

Note:
• Include only ordinary securities here – other classes of
equity securities cannot be added
• Include here (if applicable) the securities the subject of
the Appendix 3B to which this form is annexed
• It may be useful to set out issues of securities on
different dates as separate line items
Subtractthe number of fully paid+ordinary securities	2,000,000
cancelled during that 12 month period
“A”	129,615,462

Step 2: Calculate 15% of “A”

Step 2: Calculate 15% of “A”	Step 2: Calculate 15% of “A”
“B”	0.15 [Note: this value cannot be changed]
Multiply“A” by 0.15	19,442,319

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B

Page 8

Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used

Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used
	Insertnumber of+equity securities issued or agreed to be issued in that 12 month periodnot countingthose issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 Note: • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items	8,625,355
	“C”	8,625,355

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1
	“A” x 0.15 Note: number must be same as shown in Step 2	19,442,319
	Subtract“C”,, Note: number must be same as shown in Step 3	8,625,355
	Total[“A” x 0.15] – “C”	10,816,964 [Note: this is the remaining placement capacity under rule 7.1]

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B

Page 9

Part 2

Rule 7.1A – Additional placement capacity for eligible entities

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated “A” 129,615,462 Note: number must be same as shown in Step 1 of Part 1

Step 2: Calculate 10% of “A”

Step 2: Calculate 10% of “A”	Step 2: Calculate 10% of “A”
“D”	0.10 Note: this value cannot be changed
Multiply“A” by 0.10	12,961,546

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

Insert number of[+] equity securities issued or agreed to be 12,961,546 issued in that 12 month period under rule 7.1A

Notes:

• This applies to equity securities – not just ordinary securities

• • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed

• • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

• • It may be useful to set out issues of securities on different dates as separate line items

• “E” 12,961,546

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A
	“A” x 0.10 Note: number must be same as shown in Step 2	12,961,546
	Subtract“E” Note: number must be same as shown in Step 3	12,961,546
	Total[“A” x 0.10] – “E”	0 [Note: this is the remaining placement capacity under rule 7.1A]

• See chapter 19 for defined terms. 07/07/2016

Appendix 3B

Page 10

==> picture [197 x 56] intentionally omitted <==

Notice Under Section 708A (5) of the Corporations Act (ASX Code: IMC)

This notice is given under paragraph (5)(e) of section 708A of the Corporations Act.

Type	Shares	Options	Options
Class	Ordinary Fully-Paid Shares	Unlisted Options	Unlisted Options
ASX code	IMC	‘New Class’	‘New Class’
Date of Issue	16 March 2018	16 March 2018	16 March 2018
Number Issued	13,162,744	7,897,647	526,510
Specifics (if any)	N/A	Exercisable at $0.468 on or before 15 March 2023	Exercisable at $0.585 on or before 15 March 2023

Immuron Limited gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the "Corporations Act") that:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

2. as at the date of this notice the Company has complied with:

3. (i) the provisions of Chapter 2M Corporations Act as they apply to the Company; and

4. (ii) section 674 Corporations Act; and

5. as at the date of this notice there is no "excluded information" (as defined in subsection 708A (7) of the Corporations Act) which is required to be disclosed by the Company.

For and on behalf of the Company,

Kind Regards;

==> picture [79 x 31] intentionally omitted <==

Peter Vaughan Company Secretary Immuron Limited

==> picture [591 x 63] intentionally omitted <==